Artiva Biotherapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 204.85M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Details
| Name | Artiva Biotherapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 115 |
| Founded | 2019 |
| Ipo Date | 2024-07-19 |
| Ceo | Fred Aslan |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 12.00 |
| Isin | US04317A1079 |
| Cusip | 04317A107 |
| Cik | 1817241 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Fred Aslan M.D. | Chief Executive Officer, Principal Financial and Accounting Officer and Director |
| Dr. Gines Diego Miralles M.D. | President and Head of Research and Development |
| Jennifer Kinsbruner Bush Esq., J.D. | Chief Operating Officer |
| Christopher P. Horan | Chief Technical Operations Officer |
| Dr. Peter Flynn Ph.D. | Co-Founder and Strategic Advisor |
Contact
| Address | 5505 Morehouse Drive, Suite 100, San Diego, California 92121, United States |
| Phone | 858 267 4467 |
| Website | https://www.artivabio.com |